艾媒咨询 | 2025年中国病毒防治产业发展状况及重点企业大数据监测报告

当前，全球病毒变异迭代加速，公共卫生防控常态化需求持续凸显，叠加中国生物医药技术创新升级与政策精准赋能，病毒防治产业正迎来新一轮发展机遇与调整周期。全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国病毒防治产业发展状况及重点企业大数据监测报告》显示，2025年病毒防治产业集中度持续提升，营收前三名企业合计贡献TOP10整体营收的42.13%，研发投入累计投入达16.59亿元，头部引领效应凸显。细分领域中，以岭药业依托中药防治优势实现扭亏为盈，前三季度归母净利润实现10亿元，毛利率维持60%以上；华大基因深耕精准医学检测细分领域，前三季度营收规模超25亿元，市净率达2.29倍，展现出细分赛道的发展韧性。艾媒咨询分析师认为，2025年病毒防治产业处于调整转型期，研发创新、产品迭代及市场布局优化成为企业突破发展瓶颈、提升核心竞争力的关键，同时也将逐步筑牢公共卫生安全保障的产业根基，推动构建人类卫生健康共同体。
　　At present, the global iteration of virus variants is accelerating, and the demand for the normalization of public health prevention and control remains prominent. Coupled with the innovation and upgrading of China's biopharmaceutical technology and precise policy support, the virus prevention and control industry is ushering in a new round of development opportunities and adjustment cycle. According to the 2025 Report on the Development Status of China's Virus Prevention and Control Industry and Big Data Monitoring of Key Enterprises newly released by iiMedia Research, a world-leading third-party institution for data mining and analysis of the new economy industry, the concentration of the virus prevention and control industry continued to rise in 2025. The top three enterprises in terms of revenue contributed 42.13% of the total revenue of the top 10 enterprises combined, with a cumulative R&D investment of 1.659 billion yuan, highlighting the leading effect of head enterprises.
　　In the segmented sectors, Yiling Pharmaceutical turned losses into profits by virtue of its advantages in traditional Chinese medicine (TCM) prevention and control, achieving a net profit attributable to shareholders of listed companies of 1 billion yuan in the first three quarters with a gross profit margin maintained above 60%. BGI Genomics has deepened its layout in the segmented field of precision medical testing, recording a revenue scale of over 2.5 billion yuan in the first three quarters and a price-to-book ratio of 2.29 times, demonstrating the development resilience of the segmented track.
　　Analysts from iiMedia Research hold that the virus prevention and control industry is in a period of adjustment and transformation in 2025. R&D innovation, product iteration and optimization of market layout have become the key for enterprises to break through development bottlenecks and enhance core competitiveness. Meanwhile, this will gradually consolidate the industrial foundation for public health security and boost the building of a global community of health for all.

长盈精密：2021年第三季度报告

日盈电子:2021年第三季度报告

盈建科：2021年第三季度报告

艾媒咨询｜2024年中国生活美容及轻医美市场研究报告

随着居民生活水平的提高和审美观念的转变，美容行业逐渐形成一个庞大的产业链，从基本的护肤、化妆到整形、微整形等，美容行业的服务范围越发广泛。全球新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2024年中国生活美容及轻医美市场研究报告》数据显示，2023年中国美容行业市场规模已达2804.0亿元，预计2025年市场规模有望达到3816.0亿元。未来，科技美容将成为美容行业的一个重要发展方向。数据显示，2017-2023年间中国轻医美市场用户规模不断增长，2023年其用户规模达2354万人，预计到2025年将达3105万人。用户规模的持续增长，表明中国轻医美市场呈现快速发展趋势，整个市场仍有巨大的发展潜力。
With the improvement of residents' living standards and the change of aesthetic concepts, the beauty industry has gradually become a huge industrial chain, from basic skin care, makeup to plastic surgery, micro-plastic surgery, etc., the service range of the beauty industry is more and more extensive. According to the latest "China Life Beauty and light Medicine Beauty Market Research Report 2024" released by iiMedia Research, a third-party data mining and analysis institution in the global new economy industry, the market size of China's beauty industry has reached 280.04 billion yuan in 2023. It is expected that the market size is expected to reach 381.60 billion yuan in 2025. In the future, science and technology beauty will become an important development direction of the beauty industry. Data show that the user scale of China's light medical beauty market continues to grow between 2017 and 2023, with the user scale reaching 23.54 million in 2023 and is expected to reach 31.05 million in 2025. The continuous growth of the user scale indicates that China's light medical beauty market is showing a rapid development trend, and the entire market still has huge development potential.

美盈森：2021年第三季度报告

*ST盈方：2021年第三季度报告

盈趣科技：2021年第三季度报告

艾媒咨询 | 2025年中国商业航天产业发展状况及重点企业大数据监测报告

2025年中国商业航天处于技术攻坚与产能释放并行的关键转型期，产业整体实现质效双升、头部集聚态势加剧，正从量的积累向质的飞跃稳步迈进。全球领先的新经济产业第三方数据挖掘和分析机构iiMedia Research（艾媒咨询）最新发布的《2025年中国商业航天产业发展状况及重点企业大数据监测报告》数据显示，2025年中国商业航天产业实现质效双升，全年完成商业发射50次，占全国宇航发射总数的54%，入轨商业卫星311颗，占全年入轨卫星总数84%，标志着商业航天已成为中国航天事业的中坚力量。2025年前三季度营收规模前十家企业合计实现591.57亿元，前三名归母净利润占比近六成，头部企业凭借技术与资源优势抢占核心赛道。艾媒咨询分析师认为，2025年中国商业航天进入技术攻坚与产能释放的关键周期，技术突破聚焦降本增效，产业链协同效应凸显，市场格局持续优化。但是，产业仍面临核心零部件进口依赖、商业化盈利模式不成熟等痛点，制约长期发展。总体而言，中国商业航天正从量的积累向质的飞跃转型，技术、政策、资本的持续赋能将推动产业破解发展瓶颈，实现跨越式发展。
In 2025, China’s commercial aerospace industry is in a critical transition period with concurrent technological breakthroughs and production capacity release. The industry as a whole has achieved improvements in both quality and efficiency, with intensified concentration of leading enterprises, steadily advancing from quantitative accumulation to qualitative leap. According to the 2025 China Commercial Aerospace Industry Development Status and Key Enterprise Big Data Monitoring Report recently released by iiMedia Research, a leading global third-party data mining and analysis institution for the new economy, China’s commercial aerospace industry achieved both quality and efficiency improvements in 2025. A total of 50 commercial launches were completed throughout the year, accounting for 54% of the country’s total aerospace launches, and 311 commercial satellites were put into orbit, accounting for 84% of the total number of satellites put into orbit in the year, marking that commercial aerospace has become the backbone of China’s aerospace industry. In the first three quarters of 2025, the top 10 enterprises by revenue achieved a total revenue of 59.157 billion yuan, and the net profit attributable to parent companies of the top three enterprises accounted for nearly 60% of the total. Leading enterprises seized core tracks by virtue of their technological and resource advantages. Based on this, analysts at iiMedia Research pointed out that in 2025, China’s commercial aerospace industry entered a critical cycle of technological breakthroughs and production capacity release, with technological breakthroughs focusing on cost reduction and efficiency improvement, prominent synergistic effects of the industrial chain, and continuous optimization of the market pattern. However, the industry still faces pain points such as reliance on imports of core components and immature commercial profit models, which restrict its long-term development. In general, China’s commercial aerospace industry is transitioning from quantitative accumulation to qualitative leap, and the continuous empowerment of technology, policies, and capital will promote the industry to break through development bottlenecks and achieve leapfrog development.

盈康生命2021年第三季度报告